JP2005511491A5 - - Google Patents

Download PDF

Info

Publication number
JP2005511491A5
JP2005511491A5 JP2003511855A JP2003511855A JP2005511491A5 JP 2005511491 A5 JP2005511491 A5 JP 2005511491A5 JP 2003511855 A JP2003511855 A JP 2003511855A JP 2003511855 A JP2003511855 A JP 2003511855A JP 2005511491 A5 JP2005511491 A5 JP 2005511491A5
Authority
JP
Japan
Prior art keywords
peptide
concentration
composition
kit according
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003511855A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511491A (ja
JP4845166B2 (ja
Filing date
Publication date
Priority claimed from GBGB0117057.0A external-priority patent/GB0117057D0/en
Application filed filed Critical
Publication of JP2005511491A publication Critical patent/JP2005511491A/ja
Publication of JP2005511491A5 publication Critical patent/JP2005511491A5/ja
Application granted granted Critical
Publication of JP4845166B2 publication Critical patent/JP4845166B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003511855A 2001-07-12 2002-07-08 ゲルを形成する濃度の性腺刺激ホルモン放出ホルモン拮抗物質 Expired - Lifetime JP4845166B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0117057.0 2001-07-12
GBGB0117057.0A GB0117057D0 (en) 2001-07-12 2001-07-12 Pharmaceutical composition
PCT/GB2002/003116 WO2003006049A1 (en) 2001-07-12 2002-07-08 Gonadotropin releasing hormone antagonists in gel-forming concentrations

Publications (3)

Publication Number Publication Date
JP2005511491A JP2005511491A (ja) 2005-04-28
JP2005511491A5 true JP2005511491A5 (https=) 2007-05-24
JP4845166B2 JP4845166B2 (ja) 2011-12-28

Family

ID=9918396

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003511855A Expired - Lifetime JP4845166B2 (ja) 2001-07-12 2002-07-08 ゲルを形成する濃度の性腺刺激ホルモン放出ホルモン拮抗物質

Country Status (13)

Country Link
US (4) US20040038903A1 (https=)
EP (1) EP1404357B1 (https=)
JP (1) JP4845166B2 (https=)
AR (1) AR036337A1 (https=)
AT (1) ATE452648T1 (https=)
DE (1) DE60234831D1 (https=)
DK (1) DK1404357T3 (https=)
ES (1) ES2338217T3 (https=)
GB (1) GB0117057D0 (https=)
MY (1) MY139203A (https=)
PT (1) PT1404357E (https=)
UY (1) UY27378A1 (https=)
WO (1) WO2003006049A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
BRPI0314546B8 (pt) 2002-09-27 2021-05-25 Zentaris Gmbh composição de gel farmacêutico compreendendo peptídeos farmaceuticamente atvos com liberação sustentada, método para a produção dos mesmos kit.
WO2005035717A2 (en) 2003-10-03 2005-04-21 Thorn Bioscience, Llc Process for the synchronization of ovulation for timed breeding without heat detection
GB0511269D0 (en) 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
AU2007339280B2 (en) * 2006-12-21 2013-12-05 Stryker Corporation Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents
TWI539959B (zh) 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
RU2568839C2 (ru) 2009-04-23 2015-11-20 ДжейБиЭс Юнайтид Энимал Хэлс II ЛЛК Способ и композиция для синхронизации времени осеменения
MX2011011431A (es) * 2009-05-01 2012-02-23 Ferring Bv Composicion para el tratamiento de cancer de prostata.
JO3550B1 (ar) * 2009-05-01 2020-07-05 Ferring Int Center Sa مركب لمعالجة سرطان البروستاتا
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
LT2632934T (lt) 2010-10-27 2017-01-10 Ferring B.V. Degarelikso ir jo tarpinių darinių gamybos būdas
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013104745A1 (en) * 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
PL4512390T1 (pl) 2012-06-01 2025-09-01 Ferring B.V. Wytwarzanie degareliksu
ITMI20121638A1 (it) 2012-10-02 2014-04-03 Marco Sbracia Utilizzo di degarelix nel trattamento dell'endometriosi e di patologie ad essa correlate
EP2925339B1 (en) 2012-11-28 2020-04-29 United-AH II, LLC Method for synchronizing time of insemination in gilts
US10681261B2 (en) * 2012-11-30 2020-06-09 3I Avi, Llc Inspection system
TW201625218A (zh) * 2014-04-18 2016-07-16 Ｊｂｓ聯合動物保健有限責任公司 製造含ｇｎｒｈ凝膠之方法
BR112019014192A2 (pt) * 2017-01-30 2020-02-11 Antev Limited Composição compreendendo pelo menos um antagonista de gnrh
WO2019110688A1 (en) 2017-12-05 2019-06-13 Ferring B.V. A composition comprising degarelix for use in the treatment of breast cancer
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US200486A (en) * 1878-02-19 Improvement in apparatus for attaching harness to the shafts
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE69214818T2 (de) * 1991-04-25 1997-02-27 Romano S.-Cergue Deghenghi LHRH-Antagonisten
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5860957A (en) * 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5821230A (en) * 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US20020103131A1 (en) * 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
AR042815A1 (es) * 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
TWI539959B (zh) * 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
ES2589322T3 (es) * 2008-02-11 2016-11-11 Safety Syringes, Inc. Jeringa con protector de seguridad de aguja y clip para evitar la liberación del protector durante un proceso de reconstitución
MX2011011431A (es) * 2009-05-01 2012-02-23 Ferring Bv Composicion para el tratamiento de cancer de prostata.
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
EP2447276A1 (en) * 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
LT2632934T (lt) * 2010-10-27 2017-01-10 Ferring B.V. Degarelikso ir jo tarpinių darinių gamybos būdas
JO3755B1 (ar) * 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
KR20140063602A (ko) * 2011-07-15 2014-05-27 훼링 비.브이. 피코설페이트 조성물을 투여하여 대장내시경의 시술 시기를 조절하는 방법

Similar Documents

Publication Publication Date Title
JP2005511491A5 (https=)
JP4845166B2 (ja) ゲルを形成する濃度の性腺刺激ホルモン放出ホルモン拮抗物質
ES2298570T3 (es) Composiciones farmaceuticas que comprenden derivados de estetrol para el uso en la terapia del cancer.
JP2719233B2 (ja) 黄体形成ホルモン放出ホルモン拮抗ペプチド
RU2007101304A (ru) Модуляторы рецептора прогестерона, содержащие производные пиррол-оксиндола и применение
MXPA02010066A (es) Estratrienos sustituidos en 8beta-hidrocarbilo para uso como estrogenos selectivos.
HU217552B (hu) GnRH-antagonista peptidek
SE0100567D0 (sv) Compounds
EA200970348A1 (ru) Новые инъецируемые депо-композиции и способ получения таких композиций
HU211882A9 (en) Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
ES2206622T3 (es) Uso de un analogo de hormona liberadora de gonadotropina.
RU2004102507A (ru) Композиция с регулируемым высвобождением и способ ее получения
JP2003206240A5 (https=)
JP2005516904A5 (https=)
WO2004017961A3 (en) Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (gnrh) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer
RU2008119462A (ru) Конденсированное гетероциклическое производное, содержащая его лечебная композиция и ее применение в медицине
Chengalvala et al. GnRH agonists and antagonists in cancer therapy
CA2381461A1 (en) Lhrh antagonists having improved solubility properties
EP1877059B8 (en) Micronized tanaproget and compostions containing same
JP2522628B2 (ja) ＧｎＲＨ類似体
EP1782830A1 (en) Preventive and/or remedy for lower urinary tract diseases containing ep4 agonist
JP2021529165A5 (https=)
ATE434434T1 (de) Zusammensetzungen mit mikronisiertem tanaproget
CN114903902A (zh) GnRH受体拮抗剂联合雄激素受体拮抗剂在制备治疗前列腺癌药物中的用途
JP2003026601A (ja) 医薬組成物およびその製造法